Quantcast

Latest Sunitinib Stories

2011-07-08 00:19:00

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6).

2011-07-01 06:54:20

(Ivanhoe Newswire) "“ A new study reveals that cancer patients treated with the drugs sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared. "The damage that chemotherapy does to normal, healthy cells as it treats cancer has been well documented, but the precise effect that the new class of targeted agents has on the immune system is less well known. This study helps us answer that question," Keith...

2011-06-29 12:12:54

Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared.

2011-06-21 13:50:00

ATLANTA, June 21, 2011 /PRNewswire/ -- MDOUTLOOK®, the global oncology intelligence initiative powered by The Arcas Group, announced results from 4th Annual Quick Poll research launched immediately following this month's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

2011-06-15 02:00:00

TUEBINGEN, Germany, June 15, 2011 /PRNewswire/ -- igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC). The trial is designed to demonstrate the overall survival benefit of IMA901 in...

2011-06-05 10:00:00

DURHAM, N.C., June 5, 2011 /PRNewswire/ -- Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

2011-06-03 13:30:48

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

2011-06-01 07:00:00

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes.

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).


Word of the Day
adustion
  • The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
  • In medicine, cauterization.
The word 'adustion' comes from the Latin 'adustio', 'burning'.
Related